Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med

Immunology and Inflammation Program, Garvan Institute of Medical Research, Darlinghurst 2010, Australia.
Journal of Experimental Medicine (Impact Factor: 13.91). 08/2008; 205(7):1551-7. DOI: 10.1084/jem.20080218
Source: PubMed

ABSTRACT Hyper-immunoglobulin E syndrome (HIES) is a primary immune deficiency characterized by abnormal and devastating susceptibility to a narrow spectrum of infections, most commonly Staphylococcus aureus and Candida albicans. Recent investigations have identified mutations in STAT3 in the majority of HIES patients studied. Despite the identification of the genetic cause of HIES, the mechanisms underlying the pathological features of this disease remain to be elucidated. Here, we demonstrate a failure of CD4+ T cells harboring heterozygous STAT3 mutations to generate interleukin 17-secreting (i.e., T helper [Th]17) cells in vivo and in vitro due to a failure to express sufficient levels of the Th17-specific transcriptional regulator retinoid-related orphan receptor t. Because Th17 cells are enriched for cells with specificities against fungal antigens, our results may explain the pattern of infection susceptibility characteristic of patients with HIES. Furthermore, they underscore the importance of Th17 responses in normal host defense against the common pathogens S. aureus and C. albicans.

Download full-text


Available from: Stuart G Tangye, Aug 23, 2015
  • Source
    • "In patients with hyper- IgE syndrome, a defect in signal transducer and activator of transcription-3 (STAT3) causes a failure to generate sufficient IL-17 releasing T-cells. The consequent lack of IL-17 has been linked with the high susceptibility of these patients to Staphylococcus aureus and Candida albicans infections [12] [13]. Whilst the release of IL-17 plays a key role in preventing infection and maintaining health, the deregulation of IL- 17 promotes disease, in particular inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease (IBD). "
    [Show abstract] [Hide abstract]
    ABSTRACT: With 7.6 million deaths globally, cancer according to the World Health Organisation is still one of the leading causes of death worldwide. Interleukin 17 (IL-17) is a cytokine produced by Th17 cells, a T helper cell subset developed from an activated CD4+ T-cell. Whilst the importance of IL-17 in human autoimmune disease, inflammation, and pathogen defence reactions has already been established, its potential role in cancer progression still needs to be updated. Interestingly studies have demonstrated that IL-17 plays an intricate role in the pathophysiology of cancer, from tumorigenesis, proliferation, angiogenesis, and metastasis, to adapting the tumour in its ability to confer upon itself both immune, and chemotherapy resistance. This review will look into IL-17 and summarise the current information and data on its role in the pathophysiology of cancer as well as its potential application in the overall management of the disease.
    Mediators of Inflammation 07/2014; 2014:623759. DOI:10.1155/2014/623759 · 3.24 Impact Factor
    • "Similar observations have been made in humans, where iatrogenic leukopenia or hereditary defects in the NADPH oxidase or in the respiratory burst of myeloid cells are associated with increased susceptibility towards S. aureus infection (Heyworth et al., 2003). Humans with abnormal T cell function (including HIV/AIDS patients), atopic dermatitis, and hyper-IgE syndrome, also display increased susceptibility toward S. aureus cutaneous infection (Mathews et al., 2005; Bieber, 2008; Milner et al., 2008; Ma et al., 2008). These phenotypes can be recapitulated in mice with similar skin conditions or immune defects (Nakamura et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Staphylococcus aureus - a commensal of the human skin, nares and gastrointestinal tract - is also a leading cause of bacterial skin and soft tissue infection (SSTIs), bacteremia, sepsis, peritonitis, pneumonia and endocarditis. Antibiotic-resistant strains, designated MRSA (methicillin-resistant S. aureus), are common and represent a therapeutic challenge. Current research and development efforts seek to address the challenge of MRSA infections through vaccines and immune therapeutics. Mice have been used as experimental models for S. aureus SSTI, bacteremia, sepsis, peritonitis and endocarditis. This work led to the identification of key virulence factors, candidate vaccine antigens or immune-therapeutics that still require human clinical testing to establish efficacy. Past failures of human clinical trials raised skepticism whether the mouse is an appropriate model for S. aureus disease in humans. S. aureus causes chronic-persistent infections that, even with antibiotic or surgical intervention, reoccur in humans and in mice. Determinants of S. aureus evasion from human innate and adaptive immune responses have been identified, however only some of these are relevant in mice. Future research must integrate these insights and refine the experimental mouse models for specific S. aureus diseases to accurately predict the failure or success for candidate vaccines and immune-therapeutics.
    Journal of immunological methods 04/2014; 410. DOI:10.1016/j.jim.2014.04.007 · 2.01 Impact Factor
  • Source
    • "Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent or persistent infections of the skin, nails, oral and genital mucosae with Candida albicans, and sometimes by staphylococcal skin infections (Glocker and Grimbacher, 2010; Lilic, 2012; Puel et al., 2012; Alcais et al., 2010; Casanova and Abel, 2013). Patients with inherited or acquired T cell immunodeficiencies often suffer from CMC. Patients with autosomal dominant (AD) hyper-immunoglobulin E (IgE) syndrome (HIES) due to heterozygous loss-of-function mutations in STAT3 display CMC and a deficit of interleukin-17 (IL-17)-producing T cells (Chandesris et al., 2012; de Beaucoudrey et al., 2008; Ma et al., 2008; Milner et al., 2008; Minegishi et al., 2009; Renner et al., 2008). Biallelic mutations of IL12B or IL12RB1 in patients with Mendelian susceptibility to mycobacterial disease (MSMD) can also lead to mild CMC, due to low proportions of IL-17-pro- ducing circulating T cells (de Beaucoudrey et al., 2008; de Beaucoudrey et al., 2010; Prando et al., 2013; C. Rodríguez-Gallego, personal communication). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC). We report a biallelic missense mutation (T536I) in the adaptor molecule ACT1 in two siblings with CMC. The mutation, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors, with no effect on homodimerization. The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their T cells to IL-17E. By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines. SEFIR-independent interactions of ACT1 with other proteins, such as CD40, heat shock protein 70 (HSP70) and HSP90, were not affected by the T536I mutation. Overall, human IL-17A and IL-17F depend on ACT1 to mediate protective mucocutaneous immunity. Moreover, other ACT1-dependent IL-17 cytokines seem to be largely redundant in host defense.
    Immunity 10/2013; 39(4). DOI:10.1016/j.immuni.2013.09.002 · 19.75 Impact Factor
Show more